共 50 条
Predicting Progression to Mild Cognitive Impairment
被引:34
|作者:
Petersen, Ronald C.
[1
,2
]
Lundt, Emily S.
[2
]
Therneau, Terry M.
[2
]
Weigand, Stephen D.
[2
]
Knopman, David S.
[1
]
Mielke, Michelle M.
[2
]
Roberts, Rosebud O.
[2
]
Lowe, Val J.
[3
]
Machulda, Mary M.
[4
]
Kremers, Walter K.
[2
]
Geda, Yonas E.
[5
]
Jack, Clifford R., Jr.
[3
]
机构:
[1] Mayo Clin, Dept Neurol, 200 1st St SW, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA
[3] Mayo Clin, Dept Radiol, Rochester, MN USA
[4] Mayo Clin, Dept Psychiat & Psychol, Rochester, MN USA
[5] Mayo Clin, Dept Psychiat & Psychol, Phoenix, AZ USA
关键词:
ALZHEIMERS ASSOCIATION WORKGROUPS;
DIAGNOSTIC GUIDELINES;
NATIONAL INSTITUTE;
DISEASE PATHOPHYSIOLOGY;
RECOMMENDATIONS;
DEMENTIA;
MCI;
D O I:
10.1002/ana.25388
中图分类号:
R74 [神经病学与精神病学];
学科分类号:
摘要:
Despite much attention to the use of biomarkers for predicting Alzheimer disease, little information is available at the individual level. We used the population-based Mayo Clinic Study of Aging to estimate absolute risk of cognitive impairment by biomarker group. Risk increased with age and any biomarker abnormality. For example, a 75-year-old with abnormal amyloid and cortical thinning biomarkers has about a 20% chance of cognitive impairment by age 80 years, whereas with normal biomarkers the chance is ANN NEUROL 2019;85:155-160.
引用
下载
收藏
页码:155 / 160
页数:6
相关论文